ArticleScience China. Life sciences2026
Polysocial risk score predicts chronic kidney disease incidence and prognosis: mechanistic insights from plasma metabolome, proteome and lifestyle.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cumulative impact of multiple social determinants of health (SDHs) on chronic kidney disease (CKD) remains poorly understood. This prospective study examined the association of a polysocial risk score (PsRS) with CKD incidence and subsequent risks of cardiovascular disease (CVD) and mortality, and explored potential mediating pathways via multi-omics profiling and lifestyle factors. We analyzed 279,548 participants free of CKD at baseline and 19,761 patients with established CKD in the UK Biobank. The PsRS integrated 15 factors across economic, educational, healthcare, neighborhood, and social domains. Plasma metabolomic and proteomic profiles were analyzed to identify omics signatures associated with the PsRS. An unhealthy lifestyle score (uHLS) was derived based on body mass index, smoking, alcohol consumption, physical activity, sleep, and diet. Cox proportional hazards models were used to assess associations between the PsRS and outcomes. Mediation analyses were performed in subsets with available omics and lifestyle data. Over a median follow-up of 13 years, 6,628 incident CKD cases, 3,724 CVD events, and 2,486 deaths were documented. The PsRS demonstrated a positive association with incident CKD risk among CKD-free participants (per 1-point increase: HR=1.12; 95% CI: 1.11-1.14), as well as with CVD (HR=1.08; 95% CI: 1.07-1.10) and all-cause mortality (HR=1.12; 95% CI: 1.10-1.14) in CKD patients. The PsRS significantly improved the predictive performance of conventional clinical models across all outcomes, as indicated by increases in the C-index, net reclassification improvement, and integrated discrimination improvement. Multi-omics analyses revealed a PsRS-associated metabolomic signature (94 metabolites primarily involved in amino acids, fatty acids, and lipoproteins) and a proteomic signature (428 proteins primarily involved in immune/inflammatory responses, cellular signaling, and fibrosis). These omics signatures mediated substantial proportions of the PsRS-outcome associations (metabolomic: 16.64%-27.09%; proteomic: 53.09%-85.21%), as did the uHLS (8.26%-12.51%). In conclusion, the PsRS effectively predicts CKD development and prognosis, largely mediated through metabolomic and proteomic pathways.
Indexed as
Identifiers
42909750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.